Total Sales are Expected to Increase at a CAGR of 3.0%
The 2018 combined global prevalence of asthma and COPD was approximately 650.6 million, with asthma accounting for 53% and COPD accounting for the remaining 47%. In 2020, combined sales of asthma and COPD inhalers in the countries covered by this analysis totaled approximately $15.4bn. Of this, asthma devices accounted for 57% and COPD devices accounted for 43%.
Market drivers include the growing prevalence of asthma and COPD in certain regions due to the growing and aging population, and the introduction of lucrative triple-combination therapies. Market limiters include generic competition for certain blockbuster drug/device combos, competition for more traditional inhaled corticosteroids from triple-combination therapies, and a decline in cigarette smoking, leading to slowed growth in the prevalence of COPD in some regions.
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for inhalation-based drug delivery devices for the treatment of asthma and COPD; these include metered dose inhalers (MDIs) and dry powder inhalers (DPIs). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), and Japan. The forecast range for this report is 2020-25.
